Do Semaglutide Tablets Work as Well as Injections?

You've heard the tablet exists, now you want the honest comparison

It's a fair thing to wonder. The weekly injection has been around long enough to have a reputation; the tablet arrived in summer 2026 with a lot of coverage but not much plain-English context. Here's what the data actually shows.

The Wegovy injection at its 2.4mg maintenance dose produced an average 15% body-weight reduction over 68 weeks in the STEP 1 trial, published in the New England Journal of Medicine. The Wegovy tablet, studied in the OASIS 4 phase-3 trial (307 adults, 64 weeks), delivered an average of 13.6%, or roughly 16.6% in the group who stayed fully adherent throughout. That adherent-group figure needs the caveat attached: it reflects people who took every dose correctly, not a general population average.

So the tablet is meaningfully effective. It is also somewhat below the injection's average headline figure. The gap narrows if adherence is high, and it closes further when you consider that the injection now has a 7.2mg maintenance option approved by the MHRA in early 2026, which pushes average results closer to those seen with tirzepatide. A deeper comparison of the two formats is laid out on our semaglutide tablets versus injection page if you want the side-by-side breakdown. If you're still weighing up whether semaglutide tablets or injections suit your situation better, that page steps through the practical and clinical considerations in detail. The short answer: the tablet works, just not identically to the injection.

Why the tablet absorbs differently, and what that means on a Tuesday morning

Semaglutide is a large peptide molecule. Stomach acid degrades it, which is why the injection bypasses the gut entirely. The tablet solves this with a compound called SNAC, which temporarily raises the local pH around the tablet in the stomach and improves absorption through the stomach wall rather than the intestine.

That chemistry comes with a strict routine. The tablet goes in first thing (before coffee, before breakfast, before other medicines) with no more than about 120ml of plain water. Then you wait at least 30 minutes before anything else passes your lips. Food, coffee, a vitamin: all of it waits. If that sounds manageable, it probably is for most people. If your mornings are genuinely chaotic, it's worth thinking about honestly before you choose the tablet over the injection.

One practical checking habit: before you commit to the tablet format, run through a typical weekday morning in your head and count how many minutes you're actually awake before you eat or drink anything other than water. If the answer is reliably more than 30 minutes, the routine is a good fit. If it's closer to five minutes between alarm and kettle, the injection sidesteps the issue entirely. The NHS semaglutide medicine page covers the general administration principles for both formats.

One thing the tablet has over the injection: no refrigeration. Room-temperature storage makes it straightforwardly travel-friendly in a way that the pen, which needs to stay at 2–8°C, is not.

Side effects: broadly the same profile, with some differences in frequency

Both formats are semaglutide, so the side-effect profile is broadly the same, predominantly gastrointestinal. Nausea, loose stools, constipation, indigestion and fatigue are the most commonly reported. These tend to be most noticeable after starting treatment or stepping up a dose, and they often settle within a week or two as your system adjusts.

The OASIS 4 trial reported GI side effects in 74% of people taking the tablet, compared with 42.2% in the placebo group. That's a higher proportion than in some injection trials, though the methods differ between studies and direct comparison needs care. The severity was mostly mild to moderate.

Pancreatitis is an infrequent but serious risk with GLP-1 medicines across both routes. Severe stomach pain that radiates to the back, with or without vomiting, is a reason to stop and get urgent medical help rather than wait it out. The MHRA's Drug Safety Update index holds the relevant January 2026 communication on this for anyone who wants the regulator's own wording.

Women using oral contraceptives alongside the tablet should discuss this with their prescriber, since absorption of both can be affected in ways that vary by format and dose. These are the details a prescriber works through with you rather than a list you need to solve alone. If you want a full overview of what treatment involves, the weight-loss treatments overview covers both medicines in context.

Which format a prescriber will consider for you

Neither format is automatically the right choice. The prescriber weighs up your BMI, any weight-related conditions, your daily routine, your history with injections or oral medicines, and whether you're transferring from an existing treatment. The tablet is licensed for adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition, and lower thresholds can apply for some ethnic backgrounds under UK guidance.

If you're already established on the 2.4mg weekly injection, the MHRA's approval notes that a move directly to the 25mg tablet may be possible, subject to clinical assessment. That's a clinical conversation, not something to arrange yourself.

Detailed cost context for both formats, including what a legitimate private prescription typically includes, is on the Wegovy tablet price page. For questions about the clinical comparison rather than the cost, our page looking at whether the semaglutide tablet is as effective as the injection goes further into the evidence, and the direct effectiveness comparison page covers it from a different angle too. Our clinical team reviews every consultation personally, a prescriber reads your answers, not an algorithm.

If you'd like a prescriber to assess which format suits your situation, check your eligibility through our free consultation.